Company intelligence · NYSE: LLY

Eli Lilly and Company: pipeline and clinical trials

Eli Lilly is the developer behind four of the drugs Spectral Genomics tracks: retatrutide, orforglipron (Foundayo), lepodisiran, and muvalaplin. It is the lead sponsor of more than 240 active clinical trials, most often in obesity.

Legal name (SEC)ELI LILLY & Co
ListingNYSE: LLY
HeadquartersIndianapolis, Indiana, United States
SEC filingsEDGAR (CIK 59478)
Focus areasObesity and metabolic disease, Cardiovascular disease, Diabetes, Neuroscience, Oncology

Key points

  • Lilly sponsors 241 active trials on ClinicalTrials.gov, including 93 in Phase 3. Obesity and overweight are the most frequently listed conditions.
  • Its oral GLP-1 drug orforglipron was FDA-approved as Foundayo on April 1, 2026, for chronic weight management.
  • Lilly says its retatrutide data package is complete and plans an FDA submission in Q1 2027 (company-reported).
  • Lilly is running two Lp(a) cardiovascular outcomes trials with different drugs: lepodisiran (injectable siRNA) and muvalaplin (oral).
  • Its largest active trials include a 15,374-participant study of tirzepatide's effect on morbidity and mortality in obesity (SURMOUNT-MMO).

Tracked drug profiles

Drugs from this company that Spectral Genomics profiles in depth, with registry data and sourced analysis.

Active clinical trials

ClinicalTrials.gov lists 241 active trials with Eli Lilly and Company as lead sponsor (recruiting, not yet recruiting, active, or enrolling by invitation), retrieved Nov 19, 2026. Counts include only trials whose lead sponsor is registered as "Eli Lilly and Company".

By phase

Phase 176
Phase 1/26
Phase 245
Phase 2/31
Phase 393
Phase 411
Not applicable9

Most common conditions

  • Obesity (46)
  • Overweight (39)
  • Alzheimer Disease (15)
  • Diabetes Mellitus, Type 2 (12)
  • Neoplasm Metastasis (11)
  • Breast Neoplasms (10)
  • Carcinoma, Non-Small-Cell Lung (8)
  • Breast Cancer (7)

Conditions as registered by the sponsor; one trial can list several.

Largest active Phase 3 trials

TrialEnrollmentPrimary completion
NCT06292013
A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
17,300Mar 2029
SURMOUNT-MMO · NCT05556512
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
15,374Oct 2027
MOVE-Lp(a) · NCT07157774
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
10,450Mar 2031
NCT06383390
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
10,000Feb 2029
EMBER-4 · NCT05514054
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
8,000Oct 2027
NCT07241390
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
7,140Aug 2031
monarchE · NCT03155997
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer
5,637Mar 16, 2020
NCT07165028
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
4,500Aug 2030
ANCHOR-AD · NCT07142954
Epidemiology and Biomarker Study in Alzheimer's Disease
3,400Jul 2033
ATTAIN-1 · NCT05869903
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
3,127Jul 25, 2025

See this sponsor’s trials on ClinicalTrials.gov

Cardiometabolic strategy

Lilly's tracked drugs fall into two clusters.

Obesity and diabetes. Orforglipron is an approved oral GLP-1 drug for weight management, now submitted for type 2 diabetes. Retatrutide is an injectable triple agonist heading for an FDA submission in 2027. Together with tirzepatide, already marketed as Zepbound and Mounjaro, this gives Lilly injectable and oral options at different levels of efficacy.

Lipoprotein(a). Lepodisiran and muvalaplin target the same risk factor by different mechanisms. After pelacarsen's 2026 outcomes trial failed, these two outcomes trials, together with Amgen's olpasiran, are the main remaining tests of whether lowering Lp(a) prevents cardiovascular events.

What to watch

  • The retatrutide FDA submission, planned for Q1 2027 (company-reported).
  • An FDA decision on orforglipron for type 2 diabetes.
  • Registry changes to the two Lp(a) outcomes trials, which are logged on each drug profile.

Lilly has also publicly called for action against illegal products sold as retatrutide, which is not approved anywhere (Q3 2026 SEC filing).

Recent milestones

  1. Mar 5, 2024ACCLAIM-Lp(a), the lepodisiran cardiovascular outcomes trial, begins. Registry
  2. Sep 2, 2025MOVE-Lp(a), the muvalaplin cardiovascular outcomes trial, begins. Registry
  3. Apr 1, 2026FDA approves Foundayo (orforglipron) for chronic weight management. Regulator
  4. Aug 5, 2026Lilly reports a U.S. submission for orforglipron in type 2 diabetes and plans to submit retatrutide in Q1 2027. Company-reported
  5. Oct 29, 2026Lilly reports positive topline results for retatrutide versus Ozempic 2 mg in a head-to-head Phase 3 trial. Company-reported

Sources

  1. SEC EDGAR: Eli Lilly and Company filings (CIK 59478).Regulator
  2. Eli Lilly and Company. Form 8-K: Q2 2026 results (August 5, 2026).Company-reported
  3. Eli Lilly and Company. Form 8-K: Q3 2026 results (October 29, 2026).Company-reported
  4. U.S. Food and Drug Administration. FDA approves first new molecular entity under National Priority Voucher program (April 1, 2026).Regulator
  5. ClinicalTrials.gov: active trials with this lead sponsorRegistry

This page is for education and research. It is not investment advice, and nothing here is a recommendation to buy or sell any security. Company-reported information is labeled. See our disclaimer.